HER-TEMPO - Real world treatment-related outcomes on T-DXd in Canada

Trial Identifier: D9673R00032
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo
Start Date: April 2024
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, Ontario Oakville, Ontario, Canada, L6H1A7